Busting the Breast Cancer with AstraZeneca’s Gefitinib
Table 3
Milestones in the discovery and development of Gefitinib.
Year
Attributes
1960
Stanley Cohen isolated EGF from mouse submandibular gland [133]
1980s
Stanley Cohen discovered that EGFR has kinase activity [134], use of anti-EGFR antibodies [135], and discovery of EGFR-TKI having selective inhibition of tyrosine kinase activity [136]
1990s
Discovery of potent selective tyrosine kinase inhibitors of 4-anilinoquinazoline [127, 137]
2000s
Synthesis of Gefitinib [128], testing of efficacy of Gefitinib [13]
2002
Gefitinib approved for NSCLC [138], phase II clinical trials against breast cancer
2003
FDA approval of Gefitinib [139], clinical benefit in locally advanced/metastatic tumor with ER+ cancer